Key result
HDL-targeted therapies require reproducible functional assays and novel surrogate markers beyond HDL cholesterol to assess efficacy.
The review emphasizes that evaluating HDL-targeted therapies requires robust assays of HDL function, such as cholesterol efflux, rather than relying solely on HDL cholesterol levels.
A number of therapeutic strategies targeting high-density lipoprotein (HDL) cholesterol and reverse cholesterol transport are being developed to halt the progression of atherosclerosis or even induce regression. However, circulating HDL cholesterol levels alone represent an inadequate measure of therapeutic efficacy. Evaluation of the potential effects of HDL-targeted interventions on atherosclerosis requires reliable assays of HDL function and surrogate markers of efficacy. Promotion of macrophage cholesterol efflux and reverse cholesterol transport is thought to be one of the most important mechanisms by which HDL protects against atherosclerosis, and methods to assess this pathway in vivo are being developed. Indexes of monocyte chemotaxis, endothelial inflammation, oxidation, nitric oxide production, and thrombosis reveal other dimensions of HDL functionality. Robust, reproducible assays that can be performed widely are needed to move this field forward and permit effective assessment of the therapeutic potential of HDL-targeted therapies.
No takes yet. Share an insight, caveat, or question.
deGoma et al. (2008) conducted a review in Atherosclerosis. HDL-targeted therapies was evaluated. HDL-targeted therapies require robust, reproducible assays of HDL function and surrogate markers of efficacy beyond circulating HDL cholesterol levels to evaluate their effects on atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: